Effect of parecoxib intravenous administered compared with bupivacaine local infiltration in post surgical pain management following total abdominal hysterectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20150320001

Enrollment

Registered

2015-03-20

Start date

2014-08-13

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing total abdominal hysterrectomy parecoxib bupivacaine PCA total abdominal hysterctomy pain score

Interventions

bupivacaine 0.5% 20 mL incisional infiltration, parecoxib 40 mg IV

Experimental Drug,Experimental Device

Bupivacaine,Parecoxib

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: age 18-60 yr undergoing total abdominal hysterrectomy ASA status I-II

Exclusion criteria

Exclusion criteria: BMI > 30 kg/m2 known case or suspected OSA history of MI or CHF history of GI bleeding drug allergy to parecoxib, NSAIDs, bupivacaine mental or physical inability to use PCA serum creatinine > 1.5 mg/dL severe liver disease ( Child-Pugh Class C) stroke

Design outcomes

Primary

Measure	Time frame
pain score 2, 6, 10, 14, 26 hr after the operation asked patients for pain score in each time	—

Secondary

Measure	Time frame
morphine consumption by PCA 2, 6, 10, 14, 26 hr after the operation record morphine consumption in each time	—

Countries

Thailand

Contacts

Public ContactPenpak Jensarasart

Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital

penpak_jen@hotmail.com085-0822488

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026